A detailed history of Royal Bank Of Canada transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 32,873 shares of BMEA stock, worth $206,442. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,873
Previous 12,599 160.92%
Holding current value
$206,442
Previous $56,000 492.86%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.23 - $10.1 $85,759 - $204,767
20,274 Added 160.92%
32,873 $332,000
Q2 2024

Aug 14, 2024

BUY
$4.14 - $15.3 $34,531 - $127,617
8,341 Added 195.89%
12,599 $56,000
Q1 2024

Nov 05, 2024

SELL
$13.92 - $19.5 $116,106 - $162,649
-8,341 Reduced 66.2%
4,258 $63,000
Q1 2024

May 15, 2024

SELL
$13.92 - $19.5 $56,598 - $79,287
-4,066 Reduced 48.85%
4,258 $63,000
Q4 2023

Feb 14, 2024

BUY
$8.37 - $19.8 $48,813 - $115,473
5,832 Added 234.03%
8,324 $120,000
Q3 2023

Nov 14, 2023

SELL
$13.44 - $23.02 $77,159 - $132,157
-5,741 Reduced 69.73%
2,492 $34,000
Q2 2023

Aug 14, 2023

BUY
$21.66 - $41.8 $176,052 - $339,750
8,128 Added 7740.95%
8,233 $180,000
Q1 2023

May 15, 2023

BUY
$6.8 - $32.35 $278 - $1,326
41 Added 64.06%
105 $3,000
Q4 2022

Feb 14, 2023

BUY
$6.3 - $11.6 $31 - $58
5 Added 8.47%
64 $0
Q3 2022

Nov 14, 2022

BUY
$9.51 - $13.61 $561 - $802
59 New
59 $1,000
Q2 2022

Aug 15, 2022

SELL
$3.0 - $12.03 $3,996 - $16,023
-1,332 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$4.39 - $9.03 $15,132 - $31,126
-3,447 Reduced 72.13%
1,332 $6,000
Q4 2021

Feb 14, 2022

BUY
$7.22 - $12.72 $26,598 - $46,860
3,684 Added 336.44%
4,779 $36,000
Q3 2021

Nov 15, 2021

BUY
$10.0 - $15.99 $5,040 - $8,058
504 Added 85.28%
1,095 $13,000
Q2 2021

Aug 16, 2021

BUY
$13.65 - $20.93 $8,067 - $12,369
591 New
591 $9,000

Others Institutions Holding BMEA

About Biomea Fusion, Inc.


  • Ticker BMEA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,290,600
  • Market Cap $184M
  • Description
  • Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...
More about BMEA
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.